High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Phase < 1

Waitlist Available

Led By William J Petty, MD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial studies if high dose vitamin A can help treat lung cancer by boosting parts of the immune system that make antibodies stronger. It targets patients whose lung cancer can be removed by surgery.

Eligible Conditions

Non-Small Cell Lung Cancer
Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Presence or Absence of Germinal Centers in Resected Tissue

Secondary study objectives

Overall Survival

Presence or Absence of Tumor Necrosis

Proportion of Germinal Centers in Lymph Nodes

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Vitamin A compoundExperimental Treatment1 Intervention

Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.

Group II: Therapeutic Conventional SurgeryActive Control1 Intervention

Description Participants undergo surgical resection.

Do I qualify?Apply below to find out